Cladribine
- Generic Name
- Cladribine
- Brand Names
- Litak, Mavenclad
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClN5O3
- CAS Number
- 4291-63-8
- Unique Ingredient Identifier
- 47M74X9YT5
- Background
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
- Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)
- Associated Therapies
- -
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 18
- Registration Number
- NCT00258271
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
- Conditions
- Lymphoma, Lymphoblastic
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00199017
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
- Conditions
- Adult Acute Lymphocytic Leukemia
- Interventions
- Drug: CyclophosphamideDrug: DexamethasoneDrug: VincristineDrug: DaunorubicinDrug: AsparaginaseDrug: MethotrexateDrug: CytarabineDrug: MercaptopurineDrug: G-CSFDrug: VindesineDrug: EtoposideDrug: PrednisoloneDrug: AdriamycinDrug: ThioguanineDrug: TeniposideProcedure: CNS irradiationProcedure: Mediastinal IrradiationProcedure: Stem cell transplantation (SCT)Drug: IdarubicinDrug: FludarabineDrug: Cladribine
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1883
- Registration Number
- NCT00198991
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath
- Conditions
- Lymphoma, LymphoblasticAdult Acute Lymphocytic Leukemia T-cell
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 8
- Registration Number
- NCT00199030
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
- Conditions
- Leukemia, Myelocytic, Acute
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- University Hospital, Bonn
- Target Recruit Count
- 50
- Registration Number
- NCT00126321
- Locations
- 🇩🇪
Medical Clinic & Policlinic III, University Bonn, Bonn, Germany
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
- Conditions
- Myeloid Leukemia
- Interventions
- First Posted Date
- 2005-05-20
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 550
- Registration Number
- NCT00111345
- Locations
- 🇩🇪
University Children's Hospital Muenster, Department of Paediatric Haematology and Oncology, Muenster, North Rhine-Westphalia, Germany
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimDrug: cladribineDrug: cytarabineDrug: etoposideDrug: methotrexateDrug: mitoxantrone hydrochlorideDrug: therapeutic hydrocortisoneProcedure: allogeneic bone marrow transplantationProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantationRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 115
- Registration Number
- NCT00002805
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Cladribine in Patients With Mantle Cell Lymphoma
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 51
- Registration Number
- NCT00002879
- Locations
- 🇺🇸
CentraCare Clinic, Saint Cloud, Minnesota, United States
🇺🇸Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States
🇺🇸Altru Health Systems, Grand Forks, North Dakota, United States
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
- Conditions
- Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: FilgrastimDrug: CladribineDrug: CyclosporineDrug: Cytarabine (Ara-C)Drug: Fludarabine PhosphateDrug: IdarubicinDrug: MethylprednisoloneProcedure: Peripheral Blood Stem Cell Transplantation
- First Posted Date
- 2004-07-30
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00002833
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-04-05
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019071
- Locations
- 🇺🇸
Radiation Oncology Branch, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.